Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of patients with previously treated advanced hepatocellular carcinoma

Exelixis

12 November 2019 - Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial.

Exelixis today announced that its partner Ipsen Biopharmaceuticals received Health Canada approval of Cabometyx (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Read Exelixis press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine